The average one-year price target for Upstream Bio (NasdaqGS:UPB) has been revised to $44.37 / share. This is a decrease of ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
We are firm believers that you don’t need to wait until things get really bad to start therapy. If you're a college/graduate student, young adult, or professional dealing with anxiety, depression, ...
The last time I spoke about Upstream Bio, Inc. (UPB), it was in a Seeking Alpha article entitled "Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study." With respect to ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results